Condition: Acute Myeloid Leukemia (AML) · Sponsor: Yehui Tan
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
This description comes directly from the study's public registry record.
Yehui Tan · 8615948027438 · yhtan@jlu.edu.cn
Yuying Li · 8613944135650 · lyying1001@jlu.edu.cn
Always discuss trial participation with your own doctor first.
| The First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07023588